Stem Cells for Treatment of Bronchopleural Fistula
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02961725|
Recruitment Status : Recruiting
First Posted : November 11, 2016
Last Update Posted : November 11, 2016
Bronchopleural fistula (BF), an abnormal passage or communication between a bronchus and another part of the body, may develop when there are penetrating wounds of the thorax and after lung surgery. Without effective therapy, treatment of BF is a challenge, with a high rate of mortality and teratogenicity.
The investigators will conduct endoscopic injection of umbilical cord mesenchymal stem cells to fistula, observe the recovery of bronchopleural fistula and systemic reactions, to investigate the application of umbilical cord mesenchymal stem cells in the treatment of bronchopleural fistula.
|Condition or disease||Intervention/treatment||Phase|
|Bronchopleural Fistula||Biological: UCMSC||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Umbilical Cord Mesenchymal Stem Cells for Treatment of Bronchopleural Fistula|
|Study Start Date :||April 2016|
|Estimated Primary Completion Date :||April 2017|
|Estimated Study Completion Date :||April 2019|
Experimental: UCMSC treatment
UCMSC: umbilical cord mesenchymal stem cells
UCMSC: umbilical cord mesenchymal stem cells 3-5*10^7/5 ml
- closure of the fistula [ Time Frame: 24 weeks ]median time for fistula closure
- complication [ Time Frame: 1 year ]fever, coughing up blood, infection...
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02961725
|Contact: Yimin Zeng, Dr.||firstname.lastname@example.org|
|The Second Affiliated Hospital of Fujian Medical University||Recruiting|
|Quanzhou, Fujian, China, 362000|
|Contact: Hongzhi Gao, Dr. 0595-22766122 email@example.com|
|Principal Investigator:||Yimin Zeng, Dr.||The Second Affiliated Hospital of Fujian Medical University|